Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1 and Caspase-9/-3 activation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1 and Caspase-9/-3 activation. / Sørensen, Belinda Halling; Nielsen, Dorthe; Thorsteinsdottir, Unnur Arna; Hoffmann, Else Kay; Lambert, Ian Henry.

I: American Journal of Physiology: Cell Physiology, Bind 310, Nr. 11, 2016, s. C857-C873.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Sørensen, BH, Nielsen, D, Thorsteinsdottir, UA, Hoffmann, EK & Lambert, IH 2016, 'Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1 and Caspase-9/-3 activation', American Journal of Physiology: Cell Physiology, bind 310, nr. 11, s. C857-C873. https://doi.org/10.1152/ajpcell.00256.2015

APA

Sørensen, B. H., Nielsen, D., Thorsteinsdottir, U. A., Hoffmann, E. K., & Lambert, I. H. (2016). Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1 and Caspase-9/-3 activation. American Journal of Physiology: Cell Physiology, 310(11), C857-C873. https://doi.org/10.1152/ajpcell.00256.2015

Vancouver

Sørensen BH, Nielsen D, Thorsteinsdottir UA, Hoffmann EK, Lambert IH. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1 and Caspase-9/-3 activation. American Journal of Physiology: Cell Physiology. 2016;310(11):C857-C873. https://doi.org/10.1152/ajpcell.00256.2015

Author

Sørensen, Belinda Halling ; Nielsen, Dorthe ; Thorsteinsdottir, Unnur Arna ; Hoffmann, Else Kay ; Lambert, Ian Henry. / Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1 and Caspase-9/-3 activation. I: American Journal of Physiology: Cell Physiology. 2016 ; Bind 310, Nr. 11. s. C857-C873.

Bibtex

@article{a3fa5a878935425badd359ee7770ee51,
title = "Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1 and Caspase-9/-3 activation",
abstract = "The leucine rich repeat containing 8A (LRRC8A) protein is an essential component of the volume sensitive organic anion channel (VSOAC) and using pharmacological anion channel inhibitors (NS3728, DIDS) and LRRC8A siRNA we have investigated its role in development of Cisplatin resistance in human ovarian (A2780) and alveolar (A549) carcinoma cells. In Cisplatin-sensitive cells Cisplatin treatment increases p53-protein level as well as downstream signaling, e.g., expression of p21(Waf1/Cip1), Bax, Noxa, MDM2, and activation of caspase-9/-3. In contrast, Cisplatin-resistant cells do not enter apoptosis, i.e., their p53 and downstream signaling are reduced and caspase-activity unaltered following Cisplatin exposure. Reduced LRRC8A expression and VSOAC activity are previously shown to correlate with Cisplatin resistance and here we demonstrate that pharmacological inhibition and transient knockdown of LRRC8A reduce the protein level of p53, MDM2 and p21(Waf1/Cip1) as well as Caspase-9/-3 activation in Cisplatin-sensitive cells. Cisplatin resistance is accompanied by reduction in total LRRC8A expression (A2780) or LRRC8A expression in the plasma membrane (A549). Activation of capase-3 dependent apoptosis by TNFα-exposure or hyperosmotic cell shrinkage is almost unaffected by pharmacological anion channel inhibition. Our data indicate (i) that expression/activity of LRRC8A is essential for Cisplatin-induced increase in p53 protein level and its down-stream signaling, i.e., Caspase-9/-3 activation, expression of p21(Waf1/Cip1) and MDM2 and (ii) that down-regulation of LRRC8A-dependent osmolyte transporters contributes to acquirement of Cisplatin resistance in ovarian and lung carcinoma cells. Activation of LRRC8A containing channels is upstream to apoptotic volume decrease as hypertonic cell shrinkage induces apoptosis independent of the presence of LRRC8A.",
author = "S{\o}rensen, {Belinda Halling} and Dorthe Nielsen and Thorsteinsdottir, {Unnur Arna} and Hoffmann, {Else Kay} and Lambert, {Ian Henry}",
note = "Copyright {\textcopyright} 2016, American Journal of Physiology - Cell Physiology.",
year = "2016",
doi = "10.1152/ajpcell.00256.2015",
language = "English",
volume = "310",
pages = "C857--C873",
journal = "American Journal of Physiology: Cell Physiology",
issn = "0363-6143",
publisher = "American Physiological Society",
number = "11",

}

RIS

TY - JOUR

T1 - Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1 and Caspase-9/-3 activation

AU - Sørensen, Belinda Halling

AU - Nielsen, Dorthe

AU - Thorsteinsdottir, Unnur Arna

AU - Hoffmann, Else Kay

AU - Lambert, Ian Henry

N1 - Copyright © 2016, American Journal of Physiology - Cell Physiology.

PY - 2016

Y1 - 2016

N2 - The leucine rich repeat containing 8A (LRRC8A) protein is an essential component of the volume sensitive organic anion channel (VSOAC) and using pharmacological anion channel inhibitors (NS3728, DIDS) and LRRC8A siRNA we have investigated its role in development of Cisplatin resistance in human ovarian (A2780) and alveolar (A549) carcinoma cells. In Cisplatin-sensitive cells Cisplatin treatment increases p53-protein level as well as downstream signaling, e.g., expression of p21(Waf1/Cip1), Bax, Noxa, MDM2, and activation of caspase-9/-3. In contrast, Cisplatin-resistant cells do not enter apoptosis, i.e., their p53 and downstream signaling are reduced and caspase-activity unaltered following Cisplatin exposure. Reduced LRRC8A expression and VSOAC activity are previously shown to correlate with Cisplatin resistance and here we demonstrate that pharmacological inhibition and transient knockdown of LRRC8A reduce the protein level of p53, MDM2 and p21(Waf1/Cip1) as well as Caspase-9/-3 activation in Cisplatin-sensitive cells. Cisplatin resistance is accompanied by reduction in total LRRC8A expression (A2780) or LRRC8A expression in the plasma membrane (A549). Activation of capase-3 dependent apoptosis by TNFα-exposure or hyperosmotic cell shrinkage is almost unaffected by pharmacological anion channel inhibition. Our data indicate (i) that expression/activity of LRRC8A is essential for Cisplatin-induced increase in p53 protein level and its down-stream signaling, i.e., Caspase-9/-3 activation, expression of p21(Waf1/Cip1) and MDM2 and (ii) that down-regulation of LRRC8A-dependent osmolyte transporters contributes to acquirement of Cisplatin resistance in ovarian and lung carcinoma cells. Activation of LRRC8A containing channels is upstream to apoptotic volume decrease as hypertonic cell shrinkage induces apoptosis independent of the presence of LRRC8A.

AB - The leucine rich repeat containing 8A (LRRC8A) protein is an essential component of the volume sensitive organic anion channel (VSOAC) and using pharmacological anion channel inhibitors (NS3728, DIDS) and LRRC8A siRNA we have investigated its role in development of Cisplatin resistance in human ovarian (A2780) and alveolar (A549) carcinoma cells. In Cisplatin-sensitive cells Cisplatin treatment increases p53-protein level as well as downstream signaling, e.g., expression of p21(Waf1/Cip1), Bax, Noxa, MDM2, and activation of caspase-9/-3. In contrast, Cisplatin-resistant cells do not enter apoptosis, i.e., their p53 and downstream signaling are reduced and caspase-activity unaltered following Cisplatin exposure. Reduced LRRC8A expression and VSOAC activity are previously shown to correlate with Cisplatin resistance and here we demonstrate that pharmacological inhibition and transient knockdown of LRRC8A reduce the protein level of p53, MDM2 and p21(Waf1/Cip1) as well as Caspase-9/-3 activation in Cisplatin-sensitive cells. Cisplatin resistance is accompanied by reduction in total LRRC8A expression (A2780) or LRRC8A expression in the plasma membrane (A549). Activation of capase-3 dependent apoptosis by TNFα-exposure or hyperosmotic cell shrinkage is almost unaffected by pharmacological anion channel inhibition. Our data indicate (i) that expression/activity of LRRC8A is essential for Cisplatin-induced increase in p53 protein level and its down-stream signaling, i.e., Caspase-9/-3 activation, expression of p21(Waf1/Cip1) and MDM2 and (ii) that down-regulation of LRRC8A-dependent osmolyte transporters contributes to acquirement of Cisplatin resistance in ovarian and lung carcinoma cells. Activation of LRRC8A containing channels is upstream to apoptotic volume decrease as hypertonic cell shrinkage induces apoptosis independent of the presence of LRRC8A.

U2 - 10.1152/ajpcell.00256.2015

DO - 10.1152/ajpcell.00256.2015

M3 - Journal article

C2 - 26984736

VL - 310

SP - C857-C873

JO - American Journal of Physiology: Cell Physiology

JF - American Journal of Physiology: Cell Physiology

SN - 0363-6143

IS - 11

ER -

ID: 159092476